ATE238061T1 - Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten - Google Patents

Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Info

Publication number: ATE238061T1
Authority: AT; Austria
Prior art keywords: mitogens; cytokines; inhibition; immune responses; pathological immune
Prior art date: 1997-11-05

Application number

AT98957605T

Other languages

English (en)

Inventor

David Horwitz

Original Assignee

Univ Southern California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-05

Filing date

1998-11-05

Publication date

2003-05-15

1998-11-05 Application filed by Univ Southern California filed Critical Univ Southern California

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE238061T1 publication Critical patent/ATE238061T1/de

Links

102000004127 Cytokines Human genes 0.000 title 1
108090000695 Cytokines Proteins 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
239000003226 mitogen Substances 0.000 title 1
230000001575 pathological effect Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
108010002350 Interleukin-2 Proteins 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
239000012190 activator Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000016784 immunoglobulin production Effects 0.000 abstract 1
210000005087 mononuclear cell Anatomy 0.000 abstract 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT98957605T 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten ATE238061T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6450797P	1997-11-05	1997-11-05
PCT/US1998/023584 WO1999025366A1 (en)	1997-11-05	1998-11-05	Use of cytokines and mitogens to inhibit pathological immune responses

Publications (1)

Publication Number	Publication Date
ATE238061T1 true ATE238061T1 (de)	2003-05-15

Family

ID=22056456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98957605T ATE238061T1 (de)	1997-11-05	1998-11-05	Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Country Status (11)

Country	Link
US (1)	US6228359B1 (de)
EP (1)	EP1028738B1 (de)
JP (1)	JP4309047B2 (de)
AT (1)	ATE238061T1 (de)
AU (1)	AU747767B2 (de)
CA (1)	CA2309115C (de)
DE (1)	DE69813868T2 (de)
DK (1)	DK1028738T3 (de)
ES (1)	ES2198774T3 (de)
PT (1)	PT1028738E (de)
WO (1)	WO1999025366A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358506B1 (en)	1997-11-05	2002-03-19	University Of Southern California	Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) *	1999-05-05	2003-08-21	Horwitz David A.	Methods for the induction of professional and cytokine-producing regulatory T cells
US6803036B1 (en)	1998-03-03	2004-10-12	University Of Southern California	Use of cytokines, cells and mitogens to inhibit graft versus host disease
AU3066599A (en)	1998-03-03	1999-10-18	University Of Southern California	Use of cytokines and mitogens to inhibit graft versus host disease
AU771080B2 (en) *	1999-05-05	2004-03-11	University Of Southern California	Use of cytokines and mitogens to inhibit pathological immune responses
DE60042210D1 (de) *	1999-09-01	2009-06-25	Univ Southern California	Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
AU2007202534B2 (en) *	2000-04-11	2011-06-09	University Of Southern California	A method to prevent graft rejection using TGF-beta to induce T suppressor cells
AU5340001A (en) *	2000-04-11	2001-10-23	Univ Southern California	A method to prevent graft rejection using tgf-beta to induce t suppressor cells
JP2005514054A (ja) *	2001-12-21	2005-05-19	ユニバーシティ・オブ・サザン・カリフォルニア	プロフェッショナルおよびサイトカイン産生制御ｔ細胞の誘導のための方法
US20050202010A1 (en) *	2003-08-29	2005-09-15	Giroir Brett P.	Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8951796B2 (en)	2010-04-22	2015-02-10	University Of Southern California	Methods and compositions for expanding and stabilizing natural regulatory T cells
WO2013050529A2 (en)	2011-10-06	2013-04-11	European Molecular Biology Laboratory	Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
AU2012320597C1 (en)	2011-10-07	2015-10-15	Baxalta GmbH	oxMIF as a diagnostic marker
US20150110738A1 (en)	2012-05-04	2015-04-23	University Of Southern California	Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) *	2014-12-05	2015-01-21	King S College London	Cell expansion procedure

1998
- 1998-11-05 AU AU13827/99A patent/AU747767B2/en not_active Ceased
- 1998-11-05 ES ES98957605T patent/ES2198774T3/es not_active Expired - Lifetime
- 1998-11-05 DK DK98957605T patent/DK1028738T3/da active
- 1998-11-05 AT AT98957605T patent/ATE238061T1/de active
- 1998-11-05 PT PT98957605T patent/PT1028738E/pt unknown
- 1998-11-05 DE DE69813868T patent/DE69813868T2/de not_active Expired - Lifetime
- 1998-11-05 WO PCT/US1998/023584 patent/WO1999025366A1/en not_active Ceased
- 1998-11-05 US US09/186,771 patent/US6228359B1/en not_active Expired - Lifetime
- 1998-11-05 CA CA2309115A patent/CA2309115C/en not_active Expired - Fee Related
- 1998-11-05 JP JP2000520799A patent/JP4309047B2/ja not_active Expired - Fee Related
- 1998-11-05 EP EP98957605A patent/EP1028738B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP4309047B2 (ja)	2009-08-05
ES2198774T3 (es)	2004-02-01
DE69813868D1 (de)	2003-05-28
DK1028738T3 (da)	2003-08-11
US6228359B1 (en)	2001-05-08
JP2001523443A (ja)	2001-11-27
AU1382799A (en)	1999-06-07
AU747767B2 (en)	2002-05-23
CA2309115A1 (en)	1999-05-27
WO1999025366A1 (en)	1999-05-27
EP1028738A1 (de)	2000-08-23
EP1028738B1 (de)	2003-04-23
CA2309115C (en)	2010-10-19
DE69813868T2 (de)	2004-03-04
PT1028738E (pt)	2003-08-29

Legal Events

Date

Code

Title

Description

2003-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1028738

Country of ref document: EP

Publication	Publication Date	Title
DE69813868D1 (de)	2003-05-28	Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
ES2099158T3 (es)	1997-05-16	Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
EA199900349A1 (ru)	2000-06-26	Каталитическая субъединица теломеразы человека
ATE279181T1 (de)	2004-10-15	Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE126441T1 (de)	1995-09-15	Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
NZ294446A (en)	1999-07-29	Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
DE69734766D1 (de)	2006-01-05	Hemmstoff und stimulator der proliferation haematopoietischer stammzellen und deren anwendungen
DE3579113D1 (de)	1990-09-13	Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DK1112275T3 (da)	2003-11-24	Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
AR243600A1 (es)	1993-08-31	Un aparato para el tratamiento de muestras biologicas y microbiologicas.
ATE297036T1 (de)	2005-06-15	Verfahren und vorrichtung zum vorhersagen von menschlichen kognitiven leistung
DE69633679D1 (de)	2004-11-25	Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
DE69412377D1 (de)	1998-09-17	Bimetallisches-Metallocene Alumoxan Katalysatorsystem und seine Verwendung für die Herstellung von elastomeren Ethylencopolymerisaten
DE69435303D1 (de)	2010-09-02	Er behandlung von krankheiten bei denen eine cytok
IT8121396A0 (it)	1981-04-28	Procedimento per il trattamento, in particolare per la rigenerazione di olio usato.
DE3687097D1 (de)	1992-12-17	Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
PT77019A (de)	1983-08-01	Mittel zur behandlung von wunden
ATE119395T1 (de)	1995-03-15	Verwendung von interleukin-4 zur steigerung der neutrophilenzahl und zur behandlung von myeloid oder monocytoid leukeamie.
ATE404662T1 (de)	2008-08-15	Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
Rachman	2003	Psychotherapy of difficult cases: Flexibility and responsiveness in contemporary practice.
DE69127713D1 (de)	1997-10-30	Behandlung von Abgasen, die Silikon- und/oder Phosphorverbindungen enthalten
DE3856329D1 (de)	1999-06-10	Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE69007374D1 (de)	1994-04-21	Injektionssystem für die Behandlung von Zellen.
ATE123942T1 (de)	1995-07-15	5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
DE69936779D1 (de)	2007-09-20	Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen